BACKGROUND Eligibility for glucagon-like peptide 1 receptor agonists (GLP-1RA) and
sodium–glucose cotransporter 2 inhibitors (SGLT2i) has been expanded to patients with …

Diabetes drives an increasing burden of cardiovascular and renal disease worldwide,
motivating the search for new hypoglycemic agents that confer cardiac and renal protective …

Background The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on heart
failure (HF) outcomes and cardiovascular (CV) death in patients with varying combinations …

Abstract Aims The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with
sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly …

Importance An initial decline in estimated glomerular filtration rate (eGFR) is expected after
initiating a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and has been observed …

Aim An important characteristic of glucose‐lowering therapies (GLTs) is their ability to
prevent cardiovascular complications. We aimed to investigate the cardiorenal efficacy and …

Chronic kidney disease (CKD) is associated with increased morbidity and mortality,
especially from cardiovascular (CV) causes, and especially in people with diabetes mellitus …

The effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiovascular and
renal outcomes has not been systematically reviewed across baseline kidney function …

Background Empagliflozin reduces the risk of major heart failure outcomes in heart failure
with reduced or preserved ejection fraction. Objectives The goal of this study was to evaluate …

Aim In this subgroup analysis of STRONG‐HF, we explored the association between
changes in renal function and efficacy of rapid up‐titration of guideline‐directed medical …